Renal masses in kidney grafts provide a difficult clinical problem, as they must balance graft function with the necessity for cancer management. Cancers in the renal graft caused by donors can be classed as either ‘donor transmitted’ or ‘donor generated.’ The seminal TracerX Renal study revolutionized the knowledge of renal cell carcinoma oncogenesis by establishing that critical mutation in childhood leads to clinically detectable tumors later in adulthood. Current research showed that masses removed before transplantation results in satisfactory oncologic safety and graft function when identified pre-operatively. The post-operative care of a mass in a single kidney in the non-transplant population was similar to that of a mass in a solitary kidney in the transplant population, with an emphasis on a nephron-sparing strategy.
Masses in the renal graft are anticipated to become a more common clinical challenge as the number of kidney transplants performed each year increases, donors age, and graft survival improves.
Reference:link.springer.com/article/10.1007/s11934-020-0959-4
